Sterling Capital Management LLC Decreases Stake in Illumina, Inc. $ILMN

Sterling Capital Management LLC cut its stake in Illumina, Inc. (NASDAQ:ILMN) by 37.1% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,775 shares of the life sciences company’s stock after selling 5,766 shares during the period. Sterling Capital Management LLC’s holdings in Illumina were worth $1,205,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the stock. Elyxium Wealth LLC purchased a new position in shares of Illumina in the fourth quarter worth $25,000. Creative Capital Management Investments LLC lifted its stake in shares of Illumina by 160.0% during the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after buying an additional 120 shares during the period. Board of the Pension Protection Fund purchased a new stake in shares of Illumina during the fourth quarter valued at $26,000. TD Waterhouse Canada Inc. purchased a new stake in shares of Illumina during the fourth quarter valued at $26,000. Finally, Laurel Wealth Advisors LLC acquired a new position in shares of Illumina in the 4th quarter valued at $26,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Buying and Selling

In other Illumina news, insider Scott M. Davies sold 615 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $180.00, for a total value of $110,700.00. Following the sale, the insider owned 20,953 shares in the company, valued at approximately $3,771,540. This represents a 2.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 500 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $160.00, for a total value of $80,000.00. Following the completion of the sale, the chief accounting officer owned 14,446 shares in the company, valued at approximately $2,311,360. This represents a 3.35% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,003,769 shares of company stock valued at $155,710,908 in the last three months. 2.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

ILMN has been the subject of a number of research analyst reports. Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. JPMorgan Chase & Co. raised Illumina from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $125.00 to $185.00 in a report on Wednesday, June 10th. Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective for the company in a research note on Thursday, May 14th. Wall Street Zen downgraded Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Canaccord Genuity Group dropped their target price on Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research report on Friday, May 1st. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Illumina presently has an average rating of “Hold” and an average target price of $147.18.

Illumina Price Performance

NASDAQ:ILMN opened at $181.10 on Tuesday. Illumina, Inc. has a one year low of $88.00 and a one year high of $182.84. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. The firm has a market cap of $27.40 billion, a price-to-earnings ratio of 32.93, a PEG ratio of 3.30 and a beta of 1.50. The firm’s fifty day moving average is $150.59 and its two-hundred day moving average is $138.07.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company’s revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the business posted $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Research analysts expect that Illumina, Inc. will post 5.21 EPS for the current year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.